Swedbank AB Has $10.91 Million Stake in Halozyme Therapeutics, Inc. $HALO

Swedbank AB grew its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 10.1% during the 4th quarter, Holdings Channel.com reports. The firm owned 162,062 shares of the biopharmaceutical company’s stock after purchasing an additional 14,900 shares during the period. Swedbank AB’s holdings in Halozyme Therapeutics were worth $10,907,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in HALO. Root Financial Partners LLC acquired a new position in shares of Halozyme Therapeutics in the third quarter valued at approximately $25,000. Larson Financial Group LLC grew its position in Halozyme Therapeutics by 3,118.2% during the third quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 343 shares in the last quarter. Clearstead Advisors LLC grew its position in Halozyme Therapeutics by 107.7% during the third quarter. Clearstead Advisors LLC now owns 511 shares of the biopharmaceutical company’s stock worth $37,000 after buying an additional 265 shares in the last quarter. Penserra Capital Management LLC acquired a new position in Halozyme Therapeutics in the 3rd quarter valued at $52,000. Finally, Wexford Capital LP acquired a new position in Halozyme Therapeutics in the 3rd quarter valued at $70,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, COO Cortney Caudill sold 8,857 shares of the firm’s stock in a transaction on Tuesday, March 10th. The stock was sold at an average price of $67.64, for a total value of $599,087.48. Following the sale, the chief operating officer owned 7,055 shares of the company’s stock, valued at approximately $477,200.20. This trade represents a 55.66% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Helen Torley sold 10,000 shares of the firm’s stock in a transaction on Wednesday, May 13th. The shares were sold at an average price of $69.19, for a total value of $691,900.00. Following the completion of the sale, the chief executive officer directly owned 767,780 shares in the company, valued at approximately $53,122,698.20. This represents a 1.29% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 120,482 shares of company stock valued at $8,200,842. 2.50% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

HALO has been the subject of several analyst reports. Wall Street Zen raised Halozyme Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, May 16th. Morgan Stanley dropped their price objective on Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a report on Tuesday, May 12th. HC Wainwright lifted their price objective on Halozyme Therapeutics from $90.00 to $95.00 and gave the company a “buy” rating in a report on Wednesday, April 29th. Weiss Ratings raised Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a report on Tuesday, May 12th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a report on Wednesday, February 18th. Seven investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $80.67.

Halozyme Therapeutics Trading Up 0.6%

Shares of HALO stock opened at $68.72 on Wednesday. The stock’s fifty day moving average price is $65.94 and its two-hundred day moving average price is $68.77. The company has a market cap of $8.15 billion, a PE ratio of 24.72, a P/E/G ratio of 0.28 and a beta of 0.89. Halozyme Therapeutics, Inc. has a fifty-two week low of $51.06 and a fifty-two week high of $82.22. The company has a debt-to-equity ratio of 8.81, a quick ratio of 2.33 and a current ratio of 2.76.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share for the quarter, beating analysts’ consensus estimates of $1.54 by $0.06. The firm had revenue of $376.71 million for the quarter, compared to the consensus estimate of $358.60 million. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.The company’s revenue was up 42.2% compared to the same quarter last year. During the same quarter last year, the business posted $1.11 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. Equities analysts predict that Halozyme Therapeutics, Inc. will post 7.66 EPS for the current fiscal year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.